Rival drugmakers launch joint trial of medicines for Covid-19


A healthcare worker dressed in personal protective equipment handles a vial containing a swab sample at a mobile Covid-19 testing facility in Jakarta, Indonesia, on Wednesday, July 29, 2020. Photographer: Dimas Ardian/Bloomberg

RIVAL drugmakers AbbVie Inc, Amgen Inc and Takeda Pharmaceuticals Inc on Monday said they have begun treating patients in a trial to quickly show whether a drug from each company can be repurposed and used against COVID-19, the disease caused by the novel coronavirus.

The COVID-19 pandemic is an "all hands on deck moment," David Reese, Amgen's research and development chief told Reuters. "We wanted a trial to be able to quickly sift through multiple agents and prioritize."

Limited time offer:
Just RM5 per month.

Monthly Plan

RM13.90/month
RM5/month

Billed as RM5/month for the 1st 6 months then RM13.90 thereafters.

Annual Plan

RM12.33/month

Billed as RM148.00/year

1 month

Free Trial

For new subscribers only


Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
   

Next In Business News

Wall St set to open higher on tech boost, PCE data
US inflation rises in line with expectations in March
Gamuda Land announces retail partners for Gamuda Gardens
YNH reaffirms bondholders with remedied technical defaults
Ringgit ends firmer against US dollar
KPJ Healthcare partners with Trustr for AI-driven healthcare solutions
Homeritz stays positive amid economic challenges
Unisem expects performance boost amid semiconductor recovery
Gadang wins RM280mil data centre contract
S P Setia unveils Casaville single-storey bungalows in Setia EcoHill, Semenyih

Others Also Read